Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dequalinium chloride lozenges for sore throat symptoms in bacterial upper respiratory tract infections
ChiCTR2500098319Phase 4Recruiting
- Sponsor
- Tianjin Fifth Central Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dequalinium and cefaclor in acute pharyngitis, acute tonsillitis and chronic pharyngitis (3 arms), sponsored by Tianjin Fifth Central Hospital. Primary endpoints: VAS score for sore throat/odynophagia, Onset time and duration of pharyngalgia or odynophagia and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
dequaliniumcefaclor
03
Conditions
acute pharyngitisacute tonsillitischronic pharyngitis
Beyond the preview
Go deeper on ChiCTR2500098319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098319.